This company listing is no longer active
MGNK Stock Overview
Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and human immunodeficiency virus (HIV).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Mologen AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.005 |
| 52 Week High | €0.035 |
| 52 Week Low | €0.003 |
| Beta | 0 |
| 1 Month Change | -28.57% |
| 3 Month Change | -28.57% |
| 1 Year Change | -77.68% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.67% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| MGNK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 25.0% | -4.9% | -1.5% |
| 1Y | -77.7% | -19.9% | 0.9% |
Return vs Industry: MGNK underperformed the German Biotechs industry which returned -4% over the past year.
Return vs Market: MGNK underperformed the German Market which returned -24.2% over the past year.
Price Volatility
| MGNK volatility | |
|---|---|
| MGNK Average Weekly Movement | 83.4% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MGNK's share price has been volatile over the past 3 months.
Volatility Over Time: MGNK's weekly volatility has increased from 59% to 83% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | n/a | www.mologen.com |
Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and human immunodeficiency virus (HIV). The company’s lead product is Lefitolimod, an immunotherapeutic agent, which is in Phase III study for the treatment of metastatic colorectal cancer; Phase II trial for the treatment of small-cell lung cancer; and Phase Ib/IIa study of lefitolimod in HIV infected patients under antiretroviral therapy through collaborations with the Aarhus University Hospital in Denmark. Its lead product Lefitolimod is also under Phase I combination study with the checkpoint inhibitor Yervoy to treat advanced solid tumors in collaboration with MD Anderson Cancer Center at the University of Texas, the United States.
Mologen AG Fundamentals Summary
| MGNK fundamental statistics | |
|---|---|
| Market cap | €62.18k |
| Earnings (TTM) | -€13.67m |
| Revenue (TTM) | €386.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs MGNK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGNK income statement (TTM) | |
|---|---|
| Revenue | €386.00k |
| Cost of Revenue | €4.80m |
| Gross Profit | -€4.41m |
| Other Expenses | €9.25m |
| Earnings | -€13.67m |
Last Reported Earnings
Sep 30, 2019
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did MGNK perform over the long term?
See historical performance and comparison